OMNIAB INC
OABINASDAQTrading Snapshot
- Day Range
- $3.34 – $3.42
- 52-Week Range
- $1.30 – $3.55
- Volume
- $3.11B
- Avg Volume
- $3.28B
- Shares Outstanding
- 145.0M
- Next Earnings
- Sep 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $19M
- Last Q Revenue
- $13M
- P/E Ratio
- -9.4
- P/S Ratio
- 12.8x
- EPS (TTM)
- $-0.34
- Dividend Yield
- 0.00%
Why Investors Own OABI
- ✓High-growth profile — revenue up +6.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 32% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About OMNIAB INC
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
OmniAb, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by OmniAb, Inc.
Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday
U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 results and raised FY26 sales guidance. Other big gains include DOCS, QNST, TEAM, CRSR, OABI, PUBM, TWLO, BTG, and ROAD.
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out yesterday.
OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript
OmniAb, Inc. (OABI) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsKurt Gustafson - Executive VP of Finance & CFOMatthew Foehr -...
OmniAb (NASDAQ:OABI) Beats Q2 Estimates and Raises Full-Year Guidance
OmniAb's Q2 revenue soars to $13.4M, beating estimates, and the company raises full-year guidance. Shares rise ~7% in after-hours trading.
OmniAb Raises FY2026 Sales Guidance from $28.000M-$33.000M to $32.000M-$36.000M vs $30.807M Est
OmniAb (NASDAQ:OABI) raises FY2026 sales outlook from $28.000 million-$33.000 million to $32.000 million-$36.000 million vs $30.807 million estimate.